Advanced search    

Search: authors:"Binod Dhakal"

4 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma

In this phase I/II trial, BID, bendamustine (70, 80, or 90 mg/m2), ixazomib (4 mg), and dexamethasone (40 mg), was administered to 28 patients with relapsed and/or refractory multiple myeloma (RRMM) exposed to bortezomib and lenalidomide and refractory to at least one. A 3 + 3 dose escalation based on dose-limiting toxicities (DLTs) was employed in phase I (total 15); 2/6...

Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib

Dhakal,5 and Parameswaran Hari5 1Division of Infectious Diseases, Department of Medicine, University of Colorado, Denver, CO, USA 2Division of Infectious Diseases, Department of Medicine, Medical College

Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib

Dhakal,5 and Parameswaran Hari5 1Division of Infectious Diseases, Department of Medicine, University of Colorado, Denver, CO, USA 2Division of Infectious Diseases, Department of Medicine, Medical College

Localized Lymph Node Light Chain Amyloidosis

, Medical College of Wisconsin, 9200 W. Wisconsin Avenue, Milwaukee, WI 53226, USA Received 17 December 2014; Accepted 26 March 2015 Academic Editor: Marie-Christine Kyrtsonis Copyright © 2015 Binod ... Dhakal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original